A Phase III, 52-week, Multinational, Multicenter, Randomized, Double-blind, 2-arm Parallel Group Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) With the Fixed Dose Dual Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate (CHF 1535), Both Administered Via pMDI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Chronic obstructive pulmonary disease (COPD)

Change from baseline in pre-dose morning FEV1 at week 28 (V7)

Change from baseline in 2-hour post-dose morning FEV1 at week 28 (V7), Rate of moderate and severe COPD exacerbations over 52 weeks of treatment, SGRQ response (Decrease from baseline in total score ≥4) at Week 28, Incidence of treatment-emergent adverse events (TEAEs), adverse drug reactions (ADRs), serious ADRs, serious AEs (SAEs), severe AEs, TEAEs leading to discontinuation from study drug, and TEAEs leading to death, Incidence of treatment-emergent pneumonia, Incidence of treatment-emergent major adverse cardiovascular events (MACE).

No related papers found yet.

Bulgaria, Czechia, Hungary, Poland, Romania